Business Context and Reporting Period
This Form 8-K was filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on November 14, 2019. The filing serves to announce the company's financial results for the three and nine months ended September 30, 2019. The registrant is an emerging growth company incorporated in Delaware with principal executive offices in Alameda, California.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
No specific material changes versus prior periods are detailed in the text of this filing. The document solely references the issuance of a press release containing the comparative financial results.
Guidance, Outlook, and Risks
The filing includes a standard forward-looking statements disclaimer. It notes that actual results may differ materially from anticipated results due to factors outlined in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading "Risk Factors." The company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 14, 2019) for specific revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the referenced press release.
- Consult the most recent Form 10-K and 10-Q for detailed risk factors affecting the biotechnology sector and AgeX's specific pipeline.
- Confirm the status of the company's emerging growth company election and its impact on financial reporting standards.